SARS-CoV-2感染对 incident 糖尿病的影响按病毒变异株分析:来自国家COVID队列协作组(N3C)的发现
该回顾性队列研究利用N3C数据,比较COVID阳性成人(按病毒变异株时代分层)与COVID阴性对照或急性呼吸道疾病(ARI)对照的 incident 糖尿病风险。结果显示,各变异株时代COVID-19后1年 incident 糖尿病风险均升高,且各变异株间风险相似;Omicron变异株时代糖尿病发病的潜伏期更长,风险在180天后才出现。
要点
- COVID-19后1年 incident 糖尿病风险较COVID阴性对照升高,各变异株时代CIR介于1.13至1.17之间。
- 与ARI对照相比,各变异株时代COVID-19后 incident 糖尿病风险亦升高,CIR介于1.14至1.20之间。
- Omicron变异株时代 incident 糖尿病风险潜伏期更长,风险在180天后才出现,与其他变异株不同。
核心结论
- COVID-19后 incident 糖尿病风险在不同SARS-CoV-2变异株间相似,但Omicron变异株时代糖尿病发病的潜伏期更长。
研究设计与样本
- 回顾性队列研究,使用国家COVID队列协作组(N3C)数据,纳入COVID阳性成人,并与COVID阴性患者或急性呼吸道疾病(ARI)对照患者比较 incident 糖尿病风险。
- 队列按人口学特征、数据站点和Charlson合并症指数评分进行加权。
- 主要结局为各病毒变异株时代的 incident 糖尿病累积发病率比(CIR)。
主要发现
- COVID-19后1年 incident 糖尿病风险较COVID阴性对照升高:祖先株CIR 1.16(95% CI 1.12-1.21);Alpha株CIR 1.14(95% CI 1.11-1.17);Delta株CIR 1.17(95% CI 1.13-1.21);Omicron株CIR 1.13(95% CI 1.10-1.17)。
- COVID-19后1年 incident 糖尿病风险较ARI对照升高:祖先株CIR 1.17(95% CI 1.11-1.22);Alpha株CIR 1.14(95% CI 1.09-1.19);Delta株CIR 1.18(95% CI 1.11-1.26);Omicron株CIR 1.20(95% CI 1.13-1.27)。
- Omicron变异株时代 incident 糖尿病风险出现潜伏,与其他变异株不同,风险在180天后才出现。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The coronavirus 2019 (COVID-19) pandemic has evolved over time by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, disease severity, treatment, and prevention. There is evidence of an elevated risk of incident diabetes after COVID-19; our objective was to evaluate whether this association is consistent across time and with contemporary viral variants. RESEARCH DESIGN AND METHODS: We conducted a retrospective cohort study using National COVID Cohort Collaborative (N3C) data to evaluate incident diabetes risk among COVID-positive adults compared with COVID-negative patients or control patients with acute respiratory illness (ARI). Cohorts were weighted on demographics, data site, and Charlson comorbidity index score. The primary outcome was the cumulative incidence ratio (CIR) of incident diabetes for each viral variant era. RESULTS: Risk of incident diabetes 1 year after COVID-19 was increased for patients with any viral variant compared with COVID-negative control patients (ancestral CIR 1.16 [95% CI 1.12-1.21]; Alpha CIR 1.14 [95% CI 1.11-1.17]; Delta CIR 1.17 [95% CI 1.13-1.21]; Omicron CIR 1.13 [95% CI 1.10-1.17]) and control patients with ARI (ancestral CIR 1.17 [95% CI 1.11-1.22]; Alpha CIR 1.14 [95% CI 1.09-1.19]; Delta CIR 1.18 [95% CI 1.11-1.26]; Omicron CIR 1.20 [95% CI 1.13-1.27]). There was latency in the timing of incident diabetes risk with the Omicron variant; in contrast with other variants, the risk presented after 180 days. CONCLUSIONS: Incident diabetes risk after COVID-19 was similar across different SARS-CoV-2 variants. However, there was greater latency in diabetes onset in the Omicron variant era.
引用
- Wong R, Hall MA, Wiggen T, et al. Effect of SARS-CoV-2 Infection on Incident Diabetes by Viral Variant: Findings From the National COVID Cohort Collaborative (N3C). Diabetes Care. 2024. PMID: 39207804. doi:10.2337/dc24-1003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。